跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 70 条关于
“LRRC25”
全部
70
临床试验
31
药物
28
机构
0
资讯
11
去年
Multimodal AI System Demonstrates Superior Survival Prediction for Hepatocellular Carcinoma Immunotherapy
5年前
LRRC15-Targeted Antibody-Drug Conjugates Show Promise in Osteosarcoma Treatment
3个月前
SOTIO's LRRC15-Targeting ADC SOT106 Receives FDA Orphan Drug Designation for Osteosarcoma Treatment
9个月前
Ipsen Secures Global Rights to Novel LRRC15-Targeting ADC in $1.06 Billion Deal with Simcere Zaiming
去年
Denali Therapeutics Initiates Phase 2a Trial of BIIB122 for LRRK2-Associated Parkinson's Disease
去年
Halia Therapeutics Doses First Healthy Volunteer with Oral LRRK2 Inhibitor HT-4253 for Alzheimer's
去年
Halia Therapeutics Presents LRRK2 Inhibitor HT-4253 for Neurodegenerative Diseases at BIO Investor Forum
去年
Arvinas' ARV-102 Shows Promising Brain Penetration and LRRK2 Reduction in First-in-Human Parkinson's Trial
5个月前
Biognosys Partners with Michael J. Fox Foundation to Develop Critical LRRK2 Biomarker Assays for Parkinson's Disease
去年
Montara Therapeutics Receives $3.3M Grant from Michael J. Fox Foundation to Develop Brain-Selective LRRK2 Inhibitor for Parkinson's
第 1 页,共 2 页
上一页
下一页